238 related articles for article (PubMed ID: 17200981)
41. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
[TBL] [Abstract][Full Text] [Related]
42. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
[TBL] [Abstract][Full Text] [Related]
43. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
44. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
[TBL] [Abstract][Full Text] [Related]
45. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
List AF
Leukemia; 1996 Apr; 10 Suppl 1():S36-8. PubMed ID: 8618469
[TBL] [Abstract][Full Text] [Related]
46. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.
Weltermann A; Fonatsch C; Haas OA; Greinix HT; Kahls P; Mitterbauer G; Jäger U; Kainz B; Geissler K; Valent P; Sperr WR; Knöbl P; Schwarzinger I; Gleiss A; Lechner K
Leukemia; 2004 Feb; 18(2):293-302. PubMed ID: 14671635
[TBL] [Abstract][Full Text] [Related]
47. Expression of multidrug resistance-related markers in primary neuroblastoma.
Lu QJ; Dong F; Zhang JH; Li XH; Ma Y; Jiang WG
Chin Med J (Engl); 2004 Sep; 117(9):1358-63. PubMed ID: 15377429
[TBL] [Abstract][Full Text] [Related]
48. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
[TBL] [Abstract][Full Text] [Related]
49. [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance].
Zhang JB; Sun Y; Dong J; Liu LX; Ning F
Ai Zheng; 2005 Aug; 24(8):1015-7. PubMed ID: 16086885
[TBL] [Abstract][Full Text] [Related]
50. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Verstovsek S; Manshouri T; Smith FO; Giles FJ; Cortes J; Estey E; Kantarjian H; Keating M; Jeha S; Albitar M
Cancer; 2003 May; 97(9):2212-7. PubMed ID: 12712473
[TBL] [Abstract][Full Text] [Related]
51. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
Lo-Coco F; Cuneo A; Pane F; Cilloni D; Diverio D; Mancini M; Testoni N; Bardi A; Izzo B; Bolli N; La Starza R; Fazi P; Iacobelli S; Piciocchi A; Vignetti M; Amadori S; Mandelli F; Pelicci PG; Mecucci C; Falini B; Saglio G;
Haematologica; 2008 Jul; 93(7):1017-24. PubMed ID: 18508799
[TBL] [Abstract][Full Text] [Related]
53. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.
Chang H; Brandwein J; Yi QL; Chun K; Patterson B; Brien B
Leuk Res; 2004 Oct; 28(10):1007-11. PubMed ID: 15289011
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.
Mrózek K; Heinonen K; Bloomfield CD
Int J Hematol; 2000 Oct; 72(3):261-71. PubMed ID: 11185980
[TBL] [Abstract][Full Text] [Related]
55. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
56. [Polymorphisms of RAD51(G135C) and XRCC3(C241T) genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia].
Liu L; Yang L; Zhang Y; Xu ZF; Yu MH; Wang JX; Xiao ZJ
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):378-82. PubMed ID: 18581889
[TBL] [Abstract][Full Text] [Related]
57. Del (9q) AML: clinical and cytological characteristics and prognostic implications.
Peniket A; Wainscoat J; Side L; Daly S; Kusec R; Buck G; Wheatley K; Walker H; Chatters S; Harrison C; Boultwood J; Goldstone A; Burnett A
Br J Haematol; 2005 Apr; 129(2):210-20. PubMed ID: 15813849
[TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Tóthová E; Elbertová A; Fricová M; Kafková A; Hlebasková M; Svorcová E; Stecová N; Guman T; Raffac S
Neoplasma; 2001; 48(5):393-7. PubMed ID: 11845985
[TBL] [Abstract][Full Text] [Related]
59. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
60. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
